KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) Return on Capital Employed (2016 - 2026)

NovoCure's Return on Capital Employed history spans 12 years, with the latest figure at 31.69% for Q1 2026.

  • On a quarterly basis, Return on Capital Employed rose 158.0% to 31.69% in Q1 2026 year-over-year; TTM through Mar 2026 was 31.69%, a 158.0% increase, with the full-year FY2025 number at 19.24%, up 1977.0% from a year prior.
  • Return on Capital Employed hit 31.69% in Q1 2026 for NovoCure, down from 17.89% in the prior quarter.
  • Over the last five years, Return on Capital Employed for NVCR hit a ceiling of 4.43% in Q1 2022 and a floor of 35.89% in Q4 2024.
  • Historically, Return on Capital Employed has averaged 21.5% across 5 years, with a median of 22.0% in 2024.
  • The widest YoY moves for Return on Capital Employed: up 1800bps in 2025, down -1617bps in 2025.
  • Tracing NVCR's Return on Capital Employed over 5 years: stood at 8.74% in 2022, then plummeted by -175bps to 24.08% in 2023, then plummeted by -49bps to 35.89% in 2024, then surged by 50bps to 17.89% in 2025, then crashed by -77bps to 31.69% in 2026.
  • Business Quant data shows Return on Capital Employed for NVCR at 31.69% in Q1 2026, 17.89% in Q4 2025, and 33.5% in Q3 2025.